Biopharmaceutical wholesalers in Japan play broader roles than their counterparts overseas. Beyond logistics and distribution, wholesalers perform a variety of tasks related to finance, safety, and commercialization. Such functions are typically cited as justification for various fees, rebates, and allowances…
HOME > BUSINESS
BUSINESS
- Nipro Rolls Out Seven-Dose Syringe for Pfizer COVID-19 Vaccine
June 1, 2021
- Sanofi Introduces 1st NovoRapid Biosimilar in Japan
June 1, 2021
- Ayumi Curbs Enbrel Biosimilar Shipments in Fallout from Indian API Supply Disruption
June 1, 2021
- Pfizer Vaccine Now OK’ed for Adolescents, 1-Month Storage in Refrigerators
June 1, 2021
- Kobayashi Kako Submits Biz Improvement Plan Over Fudged Drug Filings
May 31, 2021
- EA Pharma/Kissei Seek Japan Approval of Ulcerative Colitis Drug
May 31, 2021
- AZ to Take Over Japan Synagis Rights from AbbVie in July as Global Pact Expires
May 31, 2021
- Yoshindo/Teijin Halt Enbrel Shipments as COVID-19 Stalls Indian API Supplies
May 31, 2021
- mRNA CDMO Arcalis Aims for One Stop Provider for Seed Verification, R&D, Commercial Production
May 31, 2021
- US Approves Myovant’s Relugolix Combo for Uterine Fibroids
May 28, 2021
- Astellas Shoots for Annual 8% Growth through FY2025: 5-Year Plan
May 27, 2021
- Nipro to Manufacture AstraZeneca COVID-19 Vaccine from June
May 27, 2021
- Daiichi Sankyo’s Humira Biosimilar Now Available in Japan
May 27, 2021
- Takeda Stepping Up Work to Improve Japanese Ecosystem for Rare Diseases
May 27, 2021
- Sawai, Towa Post Domestic Sales Growth in FY2020, but Nichi-Iko Falters on GMP Violations: Jiho Tally
May 26, 2021
- Nihon Generic Recalling Ursodeoxycholic Acid Drug over Human Hair Contamination
May 25, 2021
- Takeda’s Dengue Vaccine Shows Long-Term Efficacy
May 25, 2021
- Flawed Stability Tests Found for 31 Choseido-Manufactured Products, Recalls Hit 15
May 25, 2021
- Novartis Aims to Become Leader in Japan MS Market with Kesimpta Rollout
May 25, 2021
- Japan Ethical Drug Market Contracts 1% in Jan.-Mar.; Keytruda Top-Selling Drug for 8th Quarter Running: IQVIA
May 25, 2021
ページ
With its first “off-year” drug price revision implemented this April, Japan has now wrapped up all the reform plans agreed upon by four state ministers in 2016 for pharmaceutical pricing. As the government has provided no further mid-term vision for…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…